ITR2 Antibody

What is ITGA2 and why is it significant in research?

ITGA2 (Integrin Alpha 2) is a transmembrane protein that facilitates cell-extracellular matrix interactions, also known as focal adhesions. This protein plays critical roles in mediating adhesions to extracellular matrix components including fibronectin, vitronectin, collagen and laminin. The integrin molecule consists of two protein subunits—alpha and beta—each containing an extracellular domain, a single transmembrane domain, and a cytoplasmic domain. ITGA2 is also referred to as CD49b or VLA2 in scientific literature and is widely expressed in epithelial tissues, making it an important target for studies on tissue development, homeostasis, and disease mechanisms .

What types of ITGA2 antibodies are available for research applications?

Researchers can utilize several types of antibodies targeting ITGA2, including monoclonal and polyclonal options. Monoclonal antibodies, such as the Mouse IgG1 Kappa against human ITGA2, offer high specificity with defined epitope recognition . Polyclonal antibodies, like the rabbit polyclonal anti-ITGA2, provide broader epitope coverage which can be advantageous for certain applications . These antibodies are typically validated for multiple applications including Western blotting, immunocytochemistry (ICC), immunohistochemistry on paraffin-embedded samples (IHC-P), immunohistochemistry on frozen sections (IHC-F), and enzyme-linked immunosorbent assay (ELISA) .

How specific are ITGA2 antibodies across species?

Many commercially available ITGA2 antibodies demonstrate cross-reactivity between human and rodent samples, making them valuable for comparative studies. For instance, certain anti-ITGA2 antibodies are validated on mouse tissue and recommended for immunofluorescence labeling, IHC, or Western blot applications using materials from both rodent and human tissues . When selecting an antibody for cross-species applications, researchers should verify the validation data for each specific species of interest and consider potential variations in epitope recognition that might affect experimental outcomes.

What are the optimal dilutions for different experimental applications of ITGA2 antibodies?

The optimal working dilutions for ITGA2 antibodies vary significantly depending on the application:

These ranges provide starting points, but optimal dilutions must be determined empirically by each researcher based on their specific experimental conditions, sample types, and detection systems .

How should ITGA2 antibodies be stored to maintain optimal activity?

For frequent use, ITGA2 antibodies should be stored at 4°C. For long-term storage (up to one year), store at -20°C to -80°C in a manual defrost freezer without detectable loss of activity. The antibodies are typically supplied in phosphate-buffered saline (PBS, pH 7.4) containing preservatives such as 0.02% sodium azide (NaN3) and 50% glycerol. Repeated freeze-thaw cycles should be avoided as they can compromise antibody performance and lead to loss of activity .

What controls should be included when validating ITGA2 antibody specificity?

Proper validation requires several controls. Positive controls should include recombinant ITGA2 protein or tissues known to express ITGA2 (such as epithelial tissues). Negative controls should include tissues from knockout models, siRNA-treated samples, or tissues naturally lacking ITGA2 expression. Additional validation steps include peptide competition assays and comparing reactivity patterns across multiple antibodies targeting different epitopes of ITGA2. Some commercial antibodies provide quality control materials containing recombinant ITGA2 fragments (such as Glu74~Val277) that can serve as positive controls in Western blotting or immunohistochemistry applications .

How can artificial intelligence accelerate ITGA2 antibody discovery and development?

Recent advances in artificial intelligence (AI) are transforming antibody discovery processes, including those for targets like ITGA2. Traditional antibody discovery involves animal immunization, screening, and successive testing rounds—a time-consuming process. AI-powered approaches now allow for epitope-driven rational design of antibodies. These methods involve computational analysis of target structures to identify potential binding sites, followed by in silico design of complementary antibody fragments. For instance, tools have been developed that compute CDR and epitope peptide complementarity, enabling de novo design of antibody sequences. These AI approaches can dramatically accelerate discovery timelines and reduce the empirical nature of traditional antibody development .

What are the considerations when using ITGA2 antibodies in multi-color flow cytometry?

When incorporating ITGA2 antibodies into multi-color flow cytometry panels, researchers must consider several factors. First, fluorophore selection should minimize spectral overlap with other markers in the panel. Second, titration of the ITGA2 antibody is essential to determine optimal signal-to-noise ratios. Third, proper compensation controls must be included to correct for spectral overlap. Additionally, because ITGA2 (CD49b) expression can vary with cell activation status and tissue origin, appropriate gating strategies must be developed. Drawing from flow cytometry methodologies used for other surface proteins, researchers should consider including unstained controls, fluorescence-minus-one (FMO) controls, and isotype controls to establish accurate gating boundaries.

What are common causes of non-specific staining when using ITGA2 antibodies in immunohistochemistry?

Non-specific staining with ITGA2 antibodies can occur due to several factors. Insufficient blocking can allow antibodies to bind non-specifically to charged proteins. Excessive antibody concentration may increase background signals, necessitating proper titration. Cross-reactivity with related proteins, particularly other integrin family members, can occur due to structural similarities. Endogenous peroxidase or alkaline phosphatase activity might cause false positives if not properly quenched. Tissue fixation procedures that alter protein conformation can also affect antibody recognition. To minimize these issues, researchers should optimize blocking conditions, perform proper antibody dilution series, include appropriate negative controls, and consider pre-adsorption with related proteins to reduce cross-reactivity.

How should conflicting results between different ITGA2 antibody-based detection methods be resolved?

When faced with discrepancies between different detection methods (e.g., Western blot showing positive results while IHC appears negative), researchers should consider several factors. Different methods detect proteins in different conformational states—Western blot recognizes denatured proteins while IHC requires native epitopes. Fixation methods can mask epitopes in IHC while having no effect on Western blot results. Expression levels might be below detection thresholds for certain methods. To resolve conflicts, researchers should: (1) verify antibody validation for each specific application, (2) use multiple antibodies targeting different epitopes, (3) employ complementary non-antibody methods like mRNA analysis, and (4) perform additional controls such as antigen retrieval optimization for IHC or different blotting conditions for Western blot.

What approaches can validate the specificity of signal in ITGA2 functional assays?

Validating specificity in functional assays requires multiple complementary approaches. Genetic approaches include using CRISPR-Cas9 knockout models, siRNA-mediated knockdown, or cells from ITGA2-deficient donors as negative controls. Pharmacological validation can employ selective inhibitors of ITGA2-dependent pathways. Multiple antibody validation involves using different antibodies targeting distinct ITGA2 epitopes to confirm consistent functional effects. Recombinant protein competition assays can determine if adding excess ITGA2 protein blocks antibody-mediated effects. Additionally, researchers should compare their results with published functional data on ITGA2 and closely related integrins to identify potential off-target effects or anomalous findings.

How might single-agent fusion antibody technology be applied to ITGA2 research?

Recent advances in antibody engineering, such as the development of single-agent fusion proteins combining an antibody with its target, present intriguing possibilities for ITGA2 research. Drawing from innovations like the IL-2/anti-IL-2 antibody complex , researchers might develop ITGA2/anti-ITGA2 fusion constructs with unique functional properties. Such constructs could potentially modulate ITGA2 signaling in novel ways, offering selective activation or inhibition of specific downstream pathways. These engineered proteins could provide more precise tools for studying ITGA2 biology and potentially form the basis for therapeutic interventions in diseases involving ITGA2 dysregulation, such as certain inflammatory conditions or cancers where integrin signaling plays a key role.

What role might ITGA2 antibodies play in studying extracellular matrix interactions in 3D tissue models?

ITGA2 antibodies are becoming increasingly valuable for investigating cell-matrix interactions in advanced 3D tissue models and organoids. These complex systems better recapitulate the physiological environment compared to traditional 2D cultures. Researchers can use fluorescently labeled ITGA2 antibodies for live imaging to track integrin dynamics during matrix remodeling and cell migration in real-time. Blocking antibodies can selectively inhibit ITGA2-mediated adhesion to specific matrix components, helping to dissect the contributions of different integrin-ECM interactions to tissue architecture and function. As 3D model technologies continue to advance, ITGA2 antibodies will likely play an essential role in revealing how integrin-matrix interactions influence tissue development, homeostasis, and disease processes.